126 related articles for article (PubMed ID: 37070619)
41. Bony expansion in skeletal metastases from carcinoma of the prostate as seen by bone scintigraphy.
Resnik CS; Garver P; Resnick D
South Med J; 1984 Oct; 77(10):1331-5. PubMed ID: 6484659
[TBL] [Abstract][Full Text] [Related]
42. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
43. Assessment of Bone Lesions with
van Es SC; Velleman T; Elias SG; Bensch F; Brouwers AH; Glaudemans AWJM; Kwee TC; Iersel MW; Maduro JH; Oosting SF; de Vries EGE; Schröder CP
J Nucl Med; 2021 Feb; 62(2):177-183. PubMed ID: 32817140
[TBL] [Abstract][Full Text] [Related]
44. The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer.
Prior JO; Barghouth G; Delaloye JF; Leyvraz S; Bischof Delaloye A
Nucl Med Commun; 2003 Jan; 24(1):29-36. PubMed ID: 12501017
[TBL] [Abstract][Full Text] [Related]
45. Antigranulocyte antibody bone marrow scans in cancer patients with metastatic bone superscan appearance.
Berná L; Torres G; Carrió I; Estorch M; Germá JR; Alonso C
Clin Nucl Med; 1994 Feb; 19(2):121-8. PubMed ID: 8187396
[TBL] [Abstract][Full Text] [Related]
46. Bone marrow scintigraphy in prostatic carcinomas.
Bourgeois P; Malarme M; Van Franck R; Wauters G; Ferremans W
Nucl Med Commun; 1991 Jan; 12(1):35-45. PubMed ID: 2023692
[TBL] [Abstract][Full Text] [Related]
47. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Caglar M; Tuncel M; Yildiz E; Karabulut E
Ann Nucl Med; 2020 Dec; 34(12):932-941. PubMed ID: 32975741
[TBL] [Abstract][Full Text] [Related]
48. "Superscan" appearance in distal renal tubular acidosis.
Ohashi K; Smith HS; Jacobs MP
Clin Nucl Med; 1991 May; 16(5):318-20. PubMed ID: 2054985
[TBL] [Abstract][Full Text] [Related]
49. [6. Quantitative Evaluation of the Bone Scintigraphy in the Prostate Cancer].
Yamamoto Y
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2017; 73(10):1087-1094. PubMed ID: 29057782
[No Abstract] [Full Text] [Related]
50. [Prospective study to assess the clinical efficacy of bone scintigraphy--some analyses of clinical data].
Akiyama Y; Yui N; Matsumoto T; Iinuma T; Ishikawa T; Nakajima T; Machida K; Nishikawa J; Iio M; Uno K
Radioisotopes; 1988 Mar; 37(3):140-7. PubMed ID: 3387601
[TBL] [Abstract][Full Text] [Related]
51. Skeletal scintigraphic findings in endemic skeletal fluorosis.
Gupta SK; Gambhir S; Mithal A; Das BK
Nucl Med Commun; 1993 May; 14(5):384-90. PubMed ID: 8510879
[TBL] [Abstract][Full Text] [Related]
52. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.
Picchio M; Spinapolice EG; Fallanca F; Crivellaro C; Giovacchini G; Gianolli L; Messa C
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):13-26. PubMed ID: 21932120
[TBL] [Abstract][Full Text] [Related]
53. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
54. Bone and skeletal muscle metastases from gastric adenocarcinoma: unusual radiographic, CT and scintigraphic features.
Narváez JA; Narváez J; Clavaguera MT; Juanola X; Valls C; Fiter J
Eur Radiol; 1998; 8(8):1366-9. PubMed ID: 9853216
[TBL] [Abstract][Full Text] [Related]
55. 99Tc(m)(V)DMSA scintigraphy in skeletal metastases and superscans arising from various malignancies: diagnosis, treatment monitoring and therapeutic implications.
Basu S; Nair N; Awasare S; Tiwari BP; Asopa R; Nair C
Br J Radiol; 2004 Apr; 77(916):347-61. PubMed ID: 15107330
[TBL] [Abstract][Full Text] [Related]
56. Bone scan index on bone scintigraphy and radiation therapy for bone metastases from cancers other than prostate and breast cancers: A retrospective observational study.
Ishibashi N; Maebayashi T; Kimura Y; Okada M
J Cancer Res Ther; 2022; 18(6):1716-1721. PubMed ID: 36412434
[TBL] [Abstract][Full Text] [Related]
57.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
58. [Clinical evaluation of bone scintigraphy in patients with prostatic cancer].
Murai N; Jinnouchi S; Hoshi H; Watanabe K; Shinkawa T
Kaku Igaku; 1986 Feb; 23(2):115-22. PubMed ID: 3712853
[No Abstract] [Full Text] [Related]
59. [Bone scintigraphy findings in patients with recently diagnosed adenocarcinoma of the prostate: relationship with prostate specific antigen levels].
Ortega A; Alonso JC; Suárez M; Domínguez P; Almoguera I; Bittini A; Gómez A; Martínez L; Herranz F; Pérez-Vázquez JM
Rev Esp Med Nucl; 2000 Oct; 19(6):409-15. PubMed ID: 11060270
[TBL] [Abstract][Full Text] [Related]
60. [Extraosseous abnormalities and artifacts in skeletal scintigraphy].
Mironov SP; Ansheles AA; Shulgin DN; Sergienko VB
Vestn Rentgenol Radiol; 2016; 97(2):85-94. PubMed ID: 27522703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
